Navigation Links
New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease
Date:4/26/2012

active substance or to any of its excipients, and in case of magnetic resonance imaging (MRI) or cardioversion. Neupro® should be removed if the patient has to undergo MRI or cardioversion to avoid skin burns.

It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the risk of postural/orthostatic hypotension associated with dopaminergic therapy and reported during Neupro® treatment. Neupro® has been associated with somnolence and episodes of sudden sleep onset. Patients treated with dopamine agonists including Neupro®, have been reported pathological gambling, increased libido and hypersexuality. Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore it is recommended to taper treatment.

Hallucinations have been reported, and patients should be informed that hallucinations can occur. Cases of cardiopulmonary fibrotic complications have been reported in some patients treated with ergot-derived dopaminergic agents. Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists. Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.

External heat, from any source should not be applied to the area of the patch. Exposure of a skin rash or irritation to direct sunlight could lead to changes in the skin color. If a generalized skin reaction (e.g. allergic rash) associated with the use of Neupro® is observed, Neupro® should be discontinued.

Caution is advised when treating patients with severe hepatic impairment or acute worsening of renal function, a dose reduction might be needed.

The incidence of some dopaminergic adverse events, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa. This should be considered when prescribi
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
4. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
5. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
10. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... results that exceed the top end of its guidance ... of 2015 increased 10 percent to $79.5 million, compared ... of 2014. The Company,s revenue guidance range for the ... increase was driven by outperformance in the System One ...
(Date:5/6/2015)... 6, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... today that it will host a conference call and ... for the period ended March 31, 2015 and to ... its clinical program for aramchol. Conference ...
(Date:5/6/2015)...   Sigma-Aldrich Corporation (NASDAQ: SIAL ) a ... a $50,000 product donation to the Reproducibility Project: ... findings from recent high-impact papers in the field of ... online research marketplace Science Exchange , the non-profit ... journal eLife. The goal of the project ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3
... Reportlinker.com announces that a new ... its catalogue: Neurostimulation ... Landscape and Market Forecasts to 2017 ... Neurostimulation Devices - Global ...
... 2011 Reportlinker.com announces that a new market ... South and Central America Drug Delivery ... http://www.reportlinker.com/p0548442/South-and-Central-America-Drug-Delivery-Devices-Market-Outlook-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory South and Central ... Summary GlobalData,s ...
Cached Medicine Technology:Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017 2
(Date:5/6/2015)... (PRWEB) May 06, 2015 Dr. Vito C. ... plastic surgeons , recently completed a medical mission trip to ... on those affected by microtia and other deformities of ... April 17 and ended on April 26, Dr. Quatela and ... Microtia is a congenital deformity where the outside of the ...
(Date:5/6/2015)... The GUARDaHEART Foundation was proud to ... with the mission of providing basic living essentials and ... on Thursday, April 30th. , Through its partnership ... for the early-detection and diagnosis of heart disease, GUARDaHEART ... testing to homeless individuals and families. , “Heart ...
(Date:5/6/2015)... Mesa, Arizona (PRWEB) May 6, ... Ventures, Inc. (MAV), an investor backed Colorado cannabis ... based Phoenician Engineering subsidiary three times since first ... achieved profitability from operations, within one year of ... the end of 2014 to over 500 today ...
(Date:5/6/2015)... The American Water Resources Association (AWRA) ... prestigious Integrated Water Resources Management (IWRM) award , recognizing ... resources projects. , An IWRM approach to water resources has ... In 2014, 12 projects were nominated for the award. The ... only the 2014 AWRA IWRM Award winner - One Water, ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Doctors who ... reported what they are calling “unprecedented” tumor control in ... on the new research. Click here to read ... pembrolizumab to 25 mesothelioma patients between March and December ... in April. , “Pembrolizumab… provides robust antitumor activity in ...
Breaking Medicine News(10 mins):Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:GUARDaHEART and Starbucks® Collaborate for Impactful Event to Help Homeless Families 2Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:Nominations Sought for Integrated Water Resources Management (IWRM) Award 2Health News:Researchers Say “Unprecedented” Mesothelioma Response Possible with Skin Cancer Drug, According to Surviving Mesothelioma 2
... tend to have fewer playmates than their non-aggressive ... comparison, non-aggressive children do better at interactions with ... findings of new research that used an important ... researchers at Arizona State University and published in ...
... emphasize physical symptoms of depression (e.g. headaches, poor appetite ... the few available empirical studies report mixed data on ... for Addiction and Mental Health (CAMH) debunks this cultural ... context when assessing a patient, leading to more accurate ...
... Mich. A new vision screening device, already shown to ... and patients a head start on treating diabetes and its ... invented by two scientists at the University of Michigan Kellogg ... stress and tissue damage that occur before the first symptoms ...
... and Inspiration to Local Heart Surgeon, PHOENIX, July ... Michael E. DeBakey, M.D. who died this past weekend ... who,performed the world,s first coronary artery bypass surgery, was ... and medical director of the,Arizona Heart Institute and Arizona ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... delivers nationwide distribution for IgeaCare,s telephony-based, nurse ... AZ, July 14 /PRNewswire/ - IgeaCare Systems USA, ... a distribution agreement with Jenne,Distributors, Inc. to offer ... authorized dealers nationwide. IgeaCare provides a,telephony-based e-call and ...
Cached Medicine News:Health News:Aggressive preschoolers found to have fewer friends than others 2Health News:Culture and depression 2Health News:'Snapshots' of eyes could serve as early warning of diabetes 2Health News:'Snapshots' of eyes could serve as early warning of diabetes 3Health News:Arizona Heart Institute Remembers Heart Surgery Pioneer Dr. Michael E. DeBakey 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 3
... refrigerator is specially designed ... blood in standard 500ml ... Standard AS3864 1997. Quiet ... utilising CFC Free refrigerant ...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
Medicine Products: